<DOC>
	<DOCNO>NCT02728622</DOCNO>
	<brief_summary>A randomize study chemotherapy versus hormonal treatment patient ovarian cancer resistant refractory platinum taxane .</brief_summary>
	<brief_title>Chemotherapy vs Hormonal Treatment Platinum-resistant Ovarian Cancer Resistant Refractory Platinum Taxane</brief_title>
	<detailed_description>Patients platinum-resistant invasive epithelial ovarian , fallopian tube peritoneal cancer randomize 1:2 either hormonal treatment Tamoxifen 40 mg daily chemotherapy investigator ` choice ( weekly paclitaxel give 1 hour infusion paclitaxel 80 mg/m2 pegylated liposomal doxorubicin 40 mg/m2 give every 4 week ) .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Patients invasive epithelial ovarian , fallopian tube peritoneal cancer , resistant treatment platinum taxane , either give combination sequentially . Patients clinical progression within 6 month end treatment primary disease relapse . Patients stable disease 6 course chemotherapy primary disease relapse treatment indicate . Patients double sCA 125 least 70 IU/Ml within 3 month end treatment primary disease relapse . Age must least 18 year . Performance status must 02 ( WHO/ECOG , appendix 1 ) . Informed consent give accord ICH/EU GCP guideline local national law Patients symptomatic brain metastasis Bilirubin great 2 x UNL ( upper normal limit ) , white blood cell count 3.0 x 109/L , neutrophil count 1.5 x 109/L , platelet count 100 x 109/L . Active infection serious underlie medical condition might prevent patient receive treatment follow . Pregnant , lactating , child bear potential patient without adequate contraception Previous treatment Tamoxifen .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>platinum-resistant</keyword>
	<keyword>endocrine treatment</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>tamoxifen</keyword>
</DOC>